

Nectar Lifesciences Ltd.



Ref. No.: NLL/CS/2025- 460

January 31, 2025

To
National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Integrated Filing (Financials) for the third quarter and nine months ended December 31, 2024

Ref.: Regulation 30 and 33 of Securities and Exchange Board of India (“SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulation”).

Dear Sir/ Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, we are submitting herewith the Integrated Filing (Financials) for the third quarter and nine months ended December 31, 2024.

This is for your kind information and records please.

Thanking you,
Yours faithfully,
For **Nectar Lifesciences Limited**


(Neha Vaishnav)
Company Secretary & Compliance Officer

NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab -140507, Tel. +91-17 62-534 001, Email : cs@necLife.com, Website : www.necLife.com, [CIN: L24232PB1995PLC016664]


Statement of Standalone Financial Results for the Quarter and Nine Months ended 31.12.2024 (Rs in Lacs)

| S. No. | Particulars | Quarter Ended | | | 9 Months Ended | | Year Ended |
|--------|---|------------------|------------------|------------------|--------------------|--------------------|--------------------|
| | | 31-Dec-24 | 30-Sep-24 | 31-Dec-23 | 31-Dec-24 | 31-Dec-23 | 31-Mar-24 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I | Income from Operations | | | | | | |
| | Sales | 50,412.39 | 49,744.73 | 51,351.66 | 1,41,908.03 | 1,41,414.78 | 1,92,583.19 |
| | Less: GST Recovered | 4,978.95 | 6,956.27 | 6,135.18 | 17,801.43 | 16,990.96 | 24,174.62 |
| | Revenue from Operations | 45,433.44 | 42,788.46 | 45,216.48 | 1,24,106.60 | 1,24,423.82 | 1,68,408.57 |
| | Other operating Income | 64.77 | 21.33 | 0.63 | 131.37 | 1.88 | 154.56 |
| II | Other Income | 57.30 | 68.94 | 48.02 | 181.32 | 1,156.16 | 1,303.00 |
| III | Total Income (I + II) | 45,555.51 | 42,878.73 | 45,265.13 | 1,24,419.29 | 1,25,581.86 | 1,69,866.13 |
| IV | Expenses | | | | | | |
| | (a) Cost of Materials consumed | 29,415.15 | 25,388.87 | 34,232.05 | 84,502.37 | 88,213.26 | 1,24,244.99 |
| | (b) Purchase of Stock in Trade | - | - | - | - | - | - |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 3,788.88 | 4,215.53 | (1,495.69) | 2,040.29 | 1,218.57 | (4,020.82) |
| | (d) Employee benefits expense | 2,450.13 | 2,417.97 | 2,162.24 | 7,266.76 | 6,072.79 | 8,467.08 |
| | (e) Finance costs | 1,712.16 | 1,980.79 | 2,484.05 | 5,690.63 | 6,298.22 | 8,714.17 |
| | (f) Depreciation and amortisation expense | 1,561.35 | 1,554.87 | 1,537.35 | 4,662.25 | 4,601.83 | 6,071.84 |
| | (g) Other expenses | 5,373.06 | 6,454.09 | 6,099.48 | 17,643.89 | 18,461.55 | 24,561.27 |
| | Total Expenses (IV) | 44,300.73 | 42,012.12 | 45,019.48 | 1,21,806.19 | 1,24,866.22 | 1,68,038.53 |
| V | Profit before exceptional items and tax (III- IV) | 1,254.78 | 866.61 | 245.65 | 2,613.10 | 715.64 | 1,827.60 |
| VI | Exceptional Items | - | - | - | - | - | - |
| VII | Profit from ordinary activities before tax (V - VI) | 1,254.78 | 866.61 | 245.65 | 2,613.10 | 715.64 | 1,827.60 |
| VIII | Tax Expense | | | | | | |
| | Current Tax | - | - | - | - | - | - |
| | Deferred Tax | 470.74 | 306.72 | 88.96 | 972.26 | 275.38 | 1,327.43 |
| IX | Profit for the period from continuing operations (VII-VIII) | 784.04 | 559.89 | 156.69 | 1,640.84 | 440.26 | 500.17 |
| | Other Comprehensive Income | | | | | | |
| | Items that will not be reclassified subsequently to profit or loss | | | | | | |
| | Remeasurement of the net defined benefit liability/asset (Net of Tax) | - | - | - | - | - | (34.19) |
| | Items that will be reclassified subsequently to profit or loss | | | | | | |
| | Foreign Exchange Translation Reserve (Net of Tax) | - | - | - | - | - | - |
| | Total Other Comprehensive Income, (Net of Tax) | - | - | - | - | - | (34.19) |
| | Total Comprehensive Income for the period | 784.04 | 559.89 | 156.69 | 1,640.84 | 440.26 | 465.98 |
| X | Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) | | | | | | |
| | a) Basic (In Rs.) - After Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |
| | b) Basic (In Rs.) - Before Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |
| | c) Diluted (In Rs.) - After Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |
| | d) Diluted (In Rs.) - Before Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |



Statement of Consolidated Financial Results for the Quarter and Nine months ended 31.12.2024 (Rs in Lacs)

| S. No. | Particulars | Quarter Ended | | | 9 Months Ended | | Year Ended |
|--------|---|------------------|------------------|------------------|--------------------|--------------------|--------------------|
| | | 31-Dec-24 | 30-Sep-24 | 31-Dec-23 | 31-Dec-24 | 31-Dec-23 | 31-Mar-24 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I | Income from Operations | | | | | | |
| | Sales | 50,412.39 | 49,744.73 | 51,351.66 | 1,41,908.03 | 1,41,414.78 | 1,92,583.19 |
| | Less: GST Recovered | 4,978.95 | 6,956.27 | 6,135.18 | 17,801.43 | 16,990.96 | 24,174.62 |
| | Revenue from Operations | 45,433.44 | 42,788.46 | 45,216.48 | 1,24,106.60 | 1,24,423.82 | 1,68,408.57 |
| | Other operating Income | 64.77 | 21.33 | 0.63 | 131.37 | 1.88 | 154.56 |
| II | Other Income | 57.30 | 68.94 | 48.02 | 181.32 | 1,156.16 | 1,303.00 |
| III | Total Income (I + II) | 45,555.51 | 42,878.73 | 45,265.13 | 1,24,419.29 | 1,25,581.86 | 1,69,866.13 |
| IV | Expenses | | | | | | |
| | (a) Cost of Materials consumed | 29,415.15 | 25,388.87 | 34,232.05 | 84,502.37 | 88,213.26 | 1,24,244.99 |
| | (b) Purchase of Stock in Trade | - | - | - | - | - | - |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 3,788.88 | 4,215.53 | (1,495.69) | 2,040.29 | 1,218.57 | (4,020.82) |
| | (d) Employee benefits expense | 2,450.13 | 2,417.97 | 2,162.24 | 7,266.76 | 6,072.79 | 8,467.08 |
| | (e) Finance costs | 1,712.16 | 1,980.79 | 2,484.05 | 5,690.63 | 6,298.22 | 8,714.17 |
| | (f) Depreciation and amortisation expense | 1,561.35 | 1,554.87 | 1,537.35 | 4,662.25 | 4,601.83 | 6,071.84 |
| | (g) Other expenses | 5,373.06 | 6,454.09 | 6,099.48 | 17,643.89 | 18,461.55 | 24,561.98 |
| | Total Expenses (IV) | 44,300.73 | 42,012.12 | 45,019.48 | 1,21,806.19 | 1,24,866.22 | 1,68,039.24 |
| V | Profit before exceptional items and tax (III- IV) | 1,254.78 | 866.61 | 245.65 | 2,613.10 | 715.64 | 1,826.89 |
| VI | Exceptional Items | - | - | - | - | - | - |
| VII | Profit from ordinary activities before tax (V - VI) | 1,254.78 | 866.61 | 245.65 | 2,613.10 | 715.64 | 1,826.89 |
| VIII | Tax Expense | | | | | | |
| | Current Tax | - | - | - | - | - | - |
| | Deferred Tax | 470.74 | 306.72 | 88.96 | 972.26 | 275.38 | 1,327.43 |
| IX | Profit for the period from continuing operations (VII-VIII) | 784.04 | 559.89 | 156.69 | 1,640.84 | 440.26 | 499.46 |
| | Other Comprehensive Income | | | | | | |
| | Items that will not be reclassified subsequently to profit or loss | | | | | | |
| | Remeasurement of the net defined benefit liability/asset (Net of Tax) | - | - | - | - | - | (34.19) |
| | Items that will be reclassified subsequently to profit or loss | | | | | | |
| | Foreign Exchange Translation Reserve (Net of Tax) | - | - | - | - | - | 0.06 |
| | Total Other Comprehensive Income, (Net of Tax) | - | - | - | - | - | (34.13) |
| | Total Comprehensive Income for the period | 784.04 | 559.89 | 156.69 | 1,640.84 | 440.26 | 465.33 |
| X | Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) | | | | | | |
| | a) Basic (In Rs.) - After Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |
| | b) Basic (In Rs.) - Before Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |
| | c) Diluted (In Rs.) - After Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |
| | d) Diluted (In Rs.) - Before Exceptional Item | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 | 0.22 |



Notes

- 1 The above financial results were reviewed by Audit Committee on January 31, 2025 and approved by the Board in its meeting held on January 31, 2025. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone and consolidated unaudited financial results for the quarter and Nine Months ended on December 31, 2024.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 4 The Company has one wholly owned subsidiary, namely NECLIFE PT, UNIPESSOAL LDA, which is Inoperative during the period ended on December 31, 2024.


Dated: 31-01-2025
Place: Chandigarh



**By Order of the Board of Directors
of Nectar Lifesciences Limited**

A handwritten signature in black ink, appearing to be "Sanjiv Goyal", written over a horizontal line.

(Sanjiv Goyal)
Chairman & Managing Director
DIN: 00002841





Independent Auditor's review report on the Quarterly and Year to date Unaudited Standalone Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of,
Nectar Lifesciences Limited,
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Nectar Lifesciences Limited ("the Company") for the quarter and nine months ended Dec 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review




is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deepak Jindal & Co.

Chartered Accountants

Firm Regn. No. 023023N



(Onkar Singh)

Partner

M. No. 514746

UDIN: 25514746BMIPRZ2993

Date: 31st January 2025

Place: Chandigarh



Independent Auditors' review report on the Quarterly and year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

To
The Board of Directors
Nectar Lifesciences Limited
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Nectar Lifesciences Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and nine months ended Dec 31, 2024 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related consolidated financial statements and been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial & accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the subsidiaries listed as below: -
 - a. NECLIFE PT, UNIPESSOAL LDA (Inoperative)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the matter in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the unaudited interim financial information of the subsidiary which have not been reviewed by their auditors, whose interim financial information excluding consolidation eliminations reflects total revenue of Nil, total net profit/ (loss) after tax of Nil, total comprehensive income of Nil for the quarter ended Dec 31, 2024 and nine months ended Dec 31, 2024 respectively, as considered in the Statement. The unaudited financial information has been approved and furnished to us by the management. Our conclusion in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information. According to the information and explanations given to us by management, this interim financial information's are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

Date: 31st January 2025
Place: Chandigarh

For Deepak Jindal & Co.
Chartered Accountants
Firm Regn. No. 023023N

Partner
M. No. 514746
UDIN: 25514746BMIPSA9237

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

| Statement on deviation / variation in utilisation of funds raised | | | | | | | |
|---|-------------------------|--|-----------------------------|----------------|--|----------------|--|
| Name of listed entity | | | | | | | |
| Mode of Fund Raising | | Public Issues / Rights Issues / Preferential Issues / QIP / Others | | | | | |
| Date of Raising Funds | | | | | | | |
| Amount Raised | | | | | | | |
| Report filed for Quarter ended | | | | | | | |
| Monitoring Agency | | applicable / not applicable | | | | | |
| Monitoring Agency Name, if applicable | | | | | | | |
| Is there a Deviation / Variation in use of funds raised | | Yes / No | | | | | |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | | | | | | | |
| If Yes, Date of shareholder Approval | | | | | | | |
| Explanation for the Deviation / Variation | | | | | | | |
| Comments of the Audit Committee after review | | | | | | | |
| Comments of the auditors, if any | | | | | | | |
| Objects for which funds have been raised and where there has been a deviation, in the following table | | | | | | | |
| Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any | |
| Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc. | | | | | | | |
| Name of Signatory Designation | | | | | | | |

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

| S. No. | Particulars | in INR crore |
|---------------|--|---------------------|
| 1 | Loans / revolving facilities like cash credit from banks / financial institutions | |
| A | Total amount outstanding as on date | |
| B | Of the total amount outstanding, amount of default as on date | |
| 2 | Unlisted debt securities i.e. NCDs and DICRPS | |
| A | Total amount outstanding as on date | |
| B | Of the total amount outstanding, amount of default as on date | |
| 3 | Total financial indebtedness of the listed entity including short-term and long term debt | |

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

| Statement on Impact of Audit Qualifications for the Financial Year ended March 31, | | | | |
|---|--|---|--|--|
| <i>(See regulation 33 of the SEBI (LODR) Regulations, 2015)</i> | | | | |
| I. | Sl. No. | Particulars | Audited Figures (as reported before adjusting for qualifications) | Adjusted Figures (audited figures after adjusting for qualifications) |
| | 1 | Turnover / Total income | - | - |
| | 2 | Total Expenditure | - | - |
| | 3 | Net Profit/(Loss) | - | - |
| | 4 | Earnings Per Share | - | - |
| | 5 | Total Assets | - | - |
| | 6 | Total Liabilities | - | - |
| | 7 | Net Worth | - | - |
| | 8 | Any other financial item(s) (as felt appropriate by the management) | - | - |
| II. | <p><u>Audit Qualification (each audit qualification separately):</u></p> <p>a. Details of Audit Qualification:</p> <p>b. Type of Audit Qualification: Qualified Opinion / Disclaimer of Opinion / Adverse Opinion</p> <p>c. Frequency of qualification: Whether appeared first time / repetitive / since how long continuing</p> <p>d. For Audit Qualification(s) where the impact is quantified by the auditor, Management's Views:</p> <p>e. For Audit Qualification(s) where the impact is not quantified by the auditor:</p> <p style="padding-left: 20px;">(i) Management's estimation on the impact of audit qualification:</p> <p style="padding-left: 20px;">(ii) If management is unable to estimate the impact, reasons for the same:</p> <p style="padding-left: 20px;">(iii) Auditors' Comments on (i) or (ii) above:</p> | | | |
| III. | <p><u>Signatories:</u></p> <ul style="list-style-type: none"> • CEO/Managing Director • CFO • Audit Committee Chairman • Statutory Auditor <p>Place:</p> <p>Date:</p> | | | |